Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE The South Africa Clinical Trial Mission
May 13, 2002
-
ARCHIVE Takeda Restructures Intellectual Property Department
May 13, 2002
-
ARCHIVE BULLETIN
May 13, 2002
-
ARCHIVE Loratadine Recommended to Be Approved as New Anti-allergic Drug
May 13, 2002
-
ARCHIVE Japanese, US, EU Patent Systems Need to Be Unified: Dr Fujino
May 13, 2002
-
ARCHIVE Abbott Aims at 20th Position in Japan: Mr Liepmann
May 13, 2002
-
ARCHIVE Debates on Healthcare Reform Start: Diet
May 13, 2002
-
ARCHIVE Wholesalers Should Take Firm Stance in Price Negotiations: FJPWA
May 13, 2002
-
ARCHIVE Original Makers to Take Tougher Stance against Patent Infringement
May 13, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
May 13, 2002
-
ARCHIVE Number of Medical Accidents at Special Function Hospitals Totals over 15,000
May 13, 2002
-
ARCHIVE Fujisawa: Overseas Sales Exceed \150 Bil.
May 13, 2002
-
ARCHIVE GL Covering All Clinical Research to Be Drafted
May 13, 2002
-
ARCHIVE Daiichi Starts Research on Thrombosis Genes with Keio Univ.
May 13, 2002
-
ARCHIVE Vital-Net, Ohmori Yakuhin Tohoku to Merge in July
April 29, 2002
-
ARCHIVE Tokai Univ. Initiates Drug Discovery Project
April 29, 2002
-
ARCHIVE Animal Study Contracts Increasing: Huntingdon Life Sciences
April 29, 2002
-
ARCHIVE RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 29, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
April 29, 2002
-
ARCHIVE Tokyo Katei Yakko Proposes New Distribution for Home Remedies
April 29, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…